Australian Committee Wants HTA Review To Begin Early In 2023
At its next meeting, the Australian committee responsible for reviewing the country's health technology assessment system will discuss feedback from stakeholders, including the pharmaceutical industry, on the draft terms of reference for the review.
You may also be interested in...
The review of Australia’s health technology assessment policy and methods will start in earnest once the terms of reference have been finalized and an independent expert is in place to oversee the review.
Drug industry group Medicines Australia says that the review of the health technology assessment system must ensure that the real impact and benefits of new products for patients are taken into account in reimbursement decisions. Other areas to be explored include the use of real-world data and managing clinical and economic uncertainty.
As talks restart this week on a future pandemic accord, the international drug industry body, the IFPMA, has reiterated its concerns over the negotiating text, saying some measures could “severely hinder responses to future pandemics.”